Cargando…
A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607078/ https://www.ncbi.nlm.nih.gov/pubmed/33178785 http://dx.doi.org/10.21037/atm-2020-71 |
| _version_ | 1783604570813890560 |
|---|---|
| author | Ravindran, Nishal Thuluvath, Paul J. |
| author_facet | Ravindran, Nishal Thuluvath, Paul J. |
| author_sort | Ravindran, Nishal |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7607078 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76070782020-11-10 A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma Ravindran, Nishal Thuluvath, Paul J. Ann Transl Med Editorial Commentary AME Publishing Company 2020-10 /pmc/articles/PMC7607078/ /pubmed/33178785 http://dx.doi.org/10.21037/atm-2020-71 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Ravindran, Nishal Thuluvath, Paul J. A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma |
| title | A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma |
| title_full | A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma |
| title_fullStr | A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma |
| title_full_unstemmed | A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma |
| title_short | A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma |
| title_sort | large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607078/ https://www.ncbi.nlm.nih.gov/pubmed/33178785 http://dx.doi.org/10.21037/atm-2020-71 |
| work_keys_str_mv | AT ravindrannishal alargerandomizedclinicaltrialisnecessarytoestablishtheroleofcamrelizumabinhepatocellularcarcinoma AT thuluvathpaulj alargerandomizedclinicaltrialisnecessarytoestablishtheroleofcamrelizumabinhepatocellularcarcinoma AT ravindrannishal largerandomizedclinicaltrialisnecessarytoestablishtheroleofcamrelizumabinhepatocellularcarcinoma AT thuluvathpaulj largerandomizedclinicaltrialisnecessarytoestablishtheroleofcamrelizumabinhepatocellularcarcinoma |